Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Tuberculosis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 112 articles:
HTML format
Text format



Single Articles


    November 2018
  1. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, Ghimire S, et al
    Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  2. STURKENBOOM MGG, Simbar N, Akkerman OW, Ghimire S, et al
    Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  3. SRIVASTAVA S, Deshpande D, Magombedze G, Gumbo T, et al
    Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  4. MAGOMBEDZE G, Pasipanodya JG, Srivastava S, Deshpande D, et al
    Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  5. SRIVASTAVA S, Deshpande D, Nuermberger E, Lee PS, et al
    The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  6. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes.
    Clin Infect Dis. 2018;67.
    PubMed     Text format    


  7. DESHPANDE D, Pasipanodya JG, Mpagama SG, Bendet P, et al
    Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  8. DESHPANDE D, Alffenaar JC, Koser CU, Dheda K, et al
    d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  9. DESHPANDE D, Pasipanodya JG, Srivastava S, Bendet P, et al
    Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  10. PASIPANODYA JG, Smythe W, Merle CS, Olliaro PL, et al
    Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  11. DESHPANDE D, Pasipanodya JG, Mpagama SG, Srivastava S, et al
    Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  12. DESHPANDE D, Srivastava S, Nuermberger E, Koeuth T, et al
    Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  13. GUMBO T, Alffenaar JC
    Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
    Clin Infect Dis. 2018;67.
    PubMed     Text format     Abstract available


  14. GANMAA D, Khudyakov P, Buyanjargal U, Jargalsaikhan B, et al
    Prevalence and determinants of QuantiFERON-diagnosed tuberculosis infection in 9,810 Mongolian schoolchildren.
    Clin Infect Dis. 2018 Nov 27. pii: 5210883. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. CUBILLOS-ANGULO JM, Arriaga MB, Silva EC, Muller BLA, et al
    Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study.
    Clin Infect Dis. 2018 Nov 24. pii: 5204461. doi: 10.1093/cid/ciy1001.
    PubMed     Text format     Abstract available


  16. DORJEE K, Topgyal S, Dorjee C, Tsundue T, et al
    High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children.
    Clin Infect Dis. 2018 Nov 20. pii: 5193441. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. RAJAN JV, Semitala FC, Mehta T, Seielstad M, et al
    A Novel, 5-Transcript, Whole-blood Gene-expression Signature for Tuberculosis Screening Among People Living With Human Immunodeficiency Virus.
    Clin Infect Dis. 2018 Nov 20. pii: 5193271. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. MIGLIORI GB
    Evolution of programmatic definitions used in tuberculosis prevention and care.
    Clin Infect Dis. 2018 Nov 20. pii: 5193464. doi: 10.1093.
    PubMed     Text format    


  19. TING DSW, Tan TE, Lim CCT
    Development and Validation of a Deep Learning System for Detection of Active Pulmonary Tuberculosis on Chest Radiographs: Clinical and Technical Considerations.
    Clin Infect Dis. 2018 Nov 12. pii: 5173988. doi: 10.1093.
    PubMed     Text format    


  20. HWANG EJ, Park S, Jin KN, Kim JI, et al
    Development and Validation of a Deep Learning-Based Automatic Detection Algorithm for Active Pulmonary Tuberculosis on Chest Radiographs.
    Clin Infect Dis. 2018 Nov 12. pii: 5174137. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. LOWENTHAL P, Lin SG, Desmond E, Shah N, et al
    Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis.
    Clin Infect Dis. 2018 Nov 1. pii: 5154873. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. TRAUER JM, Dodd PJ, Gomes MGM, Gomez GB, et al
    The Importance of Heterogeneity to the Epidemiology of Tuberculosis.
    Clin Infect Dis. 2018 Nov 1. pii: 5154892. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  23. HUANG H, Ding N, Yang T, Li C, et al
    Cross-sectional whole-genome sequencing and epidemiological study of multidrug-resistant Mycobacterium tuberculosis in China.
    Clin Infect Dis. 2018 Oct 15. pii: 5130581. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  24. LESOSKY M, Rangaka MX, Pienaar C, Coussens AK, et al
    Plasma biomarkers to detect prevalent, or predict progressive, HIV-1-associated tuberculosis.
    Clin Infect Dis. 2018 Sep 26. pii: 5106993. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. VAN KAMPEN SC, Jones R, Kisembo H, Houben RMGJ, et al
    Chronic respiratory symptoms and lung abnormalities among people with a history of tuberculosis in Uganda: a national survey.
    Clin Infect Dis. 2018 Sep 18. pii: 5099459. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. FOX GJ, Nguyen VN, Dinh NS, Nghiem LPH, et al
    Post-treatment Mortality Among Patients With Tuberculosis: A Prospective Cohort Study of 10 964 Patients in Vietnam.
    Clin Infect Dis. 2018 Sep 7. pii: 5092716. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. BUI DP, Oren E, Roe DJ, Brown HE, et al
    A Case Control Study to Identify Community Venues Associated with Genetically Clustered Multidrug-Resistant Tuberculosis Disease in Lima, Peru.
    Clin Infect Dis. 2018 Sep 5. pii: 5090843. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  28. STEIN CM, Nsereko M, Malone LL, Okware B, et al
    Long-term stability of resistance to latent M. tuberculosis infection in highly exposed TB household contacts in Kampala, Uganda.
    Clin Infect Dis. 2018 Aug 28. pii: 5085255. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. ZHAO Y, Fox T, Manning K, Stewart A, et al
    Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study.
    Clin Infect Dis. 2018 Aug 24. pii: 5079132. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  30. NGWIRA LG, Corbett EL, Khundi M, Barnes GL, et al
    Screening for tuberculosis with Xpert MTB/RIF versus fluorescent microscopy among adults newly diagnosed with HIV in rural Malawi: a cluster randomized trial (CHEPETSA).
    Clin Infect Dis. 2018 Jul 27. pii: 5060257. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. HOUBEN RMGJ, Lalli M, Kranzer K, Menzies NA, et al
    What if they don't have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis.
    Clin Infect Dis. 2018 Jul 5. pii: 5049169. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  32. SVENSSON EM, Svensson RJ, Te Brake LHM, Boeree MJ, et al
    The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67:34-41.
    PubMed     Text format     Abstract available


    May 2018
  33. GARCIA-PRATS AJ, Draper HR, Finlayson H, Winckler J, et al
    Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis.
    Clin Infect Dis. 2018 May 16. pii: 4996923. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  34. XIE YL, Cronin WA, Proschan M, Oatis R, et al
    Transmission of Mycobacterium tuberculosis from patients who are nucleic acid amplification test- negative.
    Clin Infect Dis. 2018 Apr 24. pii: 4984625. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. ZUUR MA, Pasipanodya JG, van Soolingen D, van der Werf TS, et al
    Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes.
    Clin Infect Dis. 2018 Apr 24. pii: 4984540. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  36. JOHNSON KT, Churchyard GJ, Sohn H, Dowdy DW, et al
    Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings.
    Clin Infect Dis. 2018 Mar 30. pii: 4956926. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. PASIPANODYA JG, Gumbo T
    Individualizing Tuberculosis Treatment: Are Tuberculosis Programs In High Burden Settings Ready For Prime Time Therapeutic Drug Monitoring?
    Clin Infect Dis. 2018 Mar 3. pii: 4919551. doi: 10.1093.
    PubMed     Text format    


    January 2018
  38. YU MC, Chiang CY, Lee JJ, Chien ST, et al
    Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up.
    Clin Infect Dis. 2018 Jan 31. pii: 4831095. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. MARAIS S, Roos I, Mitha A, Mabusha SJ, et al
    Spinal tuberculosis: Clinicoradiological findings in 274 patients.
    Clin Infect Dis. 2018 Jan 11. pii: 4797620. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. DEGNER NR, Wang JY, Golub JE, Karakousis PC, et al
    Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
    Clin Infect Dis. 2018;66:198-205.
    PubMed     Text format     Abstract available


    November 2017
  41. KOSER CU, Koeser LA, Dolinger DL
    Limited evidence for need for region-specific, genotypic drug-susceptibility assays for Mycobacterium tuberculosis.
    Clin Infect Dis. 2017 Nov 22. pii: 4647356. doi: 10.1093/cid/cix1042.
    PubMed     Text format    


  42. GRIESEL R, Stewart A, van der Plas H, Sikhondze W, et al
    Optimizing Tuberculosis Diagnosis in HIV-Infected Inpatients Meeting the Criteria of Seriously Ill in the WHO Algorithm.
    Clin Infect Dis. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  43. HUAMAN MA, Ticona E, Miranda G, Kryscio RJ, et al
    The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. GUTHRIE JL, Kong C, Roth D, Jorgensen D, et al
    Molecular Epidemiology of Tuberculosis in British Columbia, Canada - A 10-Year Retrospective Study.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. MARTINEZ L, Zhu L, Castellanos ME, Liu Q, et al
    Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study.
    Clin Infect Dis. 2017 Oct 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. OSMAN M, Lee K, Du Preez K, Dunbar R, et al
    Excellent Treatment Outcomes in Children Treated for Tuberculosis Under Routine Operational Conditions in Cape Town, South Africa.
    Clin Infect Dis. 2017;65:1444-1452.
    PubMed     Text format     Abstract available


  47. VANINO E, Tadolini M, Attard L, Po C, et al
    Systematic Tuberculosis Screening in Asylum Seekers in Italy.
    Clin Infect Dis. 2017;65:1407-1409.
    PubMed     Text format     Abstract available


  48. DOBLER CC
    Cumulative Incidence and Incidence Rate Ratio for Estimation of Risk of Tuberculosis in Patients With Cancer.
    Clin Infect Dis. 2017;65:1423.
    PubMed     Text format    


  49. FARHAT MR, Jacobson KR, Franke MF, Kaur D, et al
    Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.
    Clin Infect Dis. 2017;65:1364-1370.
    PubMed     Text format     Abstract available


  50. MCKENNA L, Frick M, Lee C, Namutamba D, et al
    A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials.
    Clin Infect Dis. 2017;65:1383-1387.
    PubMed     Text format     Abstract available


  51. ADU-GYAMFI CG, Snyman T, Hoffmann CJ, Martinson NA, et al
    Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients.
    Clin Infect Dis. 2017;65:1356-1358.
    PubMed     Text format     Abstract available


  52. LEE RS, Howden BP
    The Critical Importance of Sampling Fraction to Inferences of Mycobacterium tuberculosis Transmission.
    Clin Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format    


    September 2017
  53. LIN HH, Wu CY, Wang CH, Fu H, et al
    Association of obesity, diabetes, and risk of tuberculosis: two population-based cohorts.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. SALAZAR-AUSTIN N, Hoffmann J, Cohn S, Mashabela F, et al
    Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  55. SIVRO A, McKinnon LR, Yende-Zuma N, Gengiah S, et al
    Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.
    Clin Infect Dis. 2017;65:819-826.
    PubMed     Text format     Abstract available


    August 2017
  56. BACCANI I, Antonelli A, Galano A, Bartalesi F, et al
    Linezolid-resistant Enterococcus faecalis infection following prolonged low-dosage linezolid treatment for multi-drug-resistant tuberculosis.
    Clin Infect Dis. 2017 Aug 20. doi: 10.1093.
    PubMed     Text format    


  57. DRANCOURT M
    Please, no more gastric aspirate to diagnose pulmonary tuberculosis in children.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format    


  58. MUNOZ L, Santin M, Alcaide F, Ruiz-Serrano MJ, et al
    QuantiFERON(R)-TB Gold In-Tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: A non-inferiority clinical trial.
    Clin Infect Dis. 2017 Aug 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. ARGUELLO PEREZ E, Seo SK, Schneider WJ, Eisenstein C, et al
    Management of Latent Tuberculosis Infection among Healthcare Workers: 10-year Experience at a Single Center.
    Clin Infect Dis. 2017 Aug 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. SCHECHTER MC, Bizune D, Kagei M, Machaidze M, et al
    Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.
    Clin Infect Dis. 2017 Aug 3. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2017
  61. SALINAS JL, Armstrong LR, Silk BJ, Haddad MB, et al
    Factors Associated with All-Cause Mortality among Patients with Multidrug-Resistant Tuberculosis - United States, 1993-2013.
    Clin Infect Dis. 2017 Jul 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. FLORIDIA M, Ciccacci F, Andreotti M, Hassane A, et al
    Tuberculosis case finding with combined rapid point of care assays (Xpert(R) MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique.
    Clin Infect Dis. 2017 Jul 23. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  63. SMITH SE, Pratt R, Trieu L, Barry PM, et al
    Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014.
    Clin Infect Dis. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. MOORE DP, Higdon MM, Hammitt LL, Prosperi C, et al
    The Incremental Value of Repeated Induced Sputum and Gastric Aspirate Samples for the Diagnosis of Pulmonary Tuberculosis in Young Children With Acute Community-Acquired Pneumonia.
    Clin Infect Dis. 2017;64.
    PubMed     Text format     Abstract available


  65. ROHLWINK UK, Mauff K, Wilkinson KA, Enslin N, et al
    Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis.
    Clin Infect Dis. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  66. SANDUL AL, Nwana N, Holcombe JM, Lobato MN, et al
    High Rate of Treatment Completion in Program Settings with 12-Dose Weekly Isoniazid and Rifapentine (3HP) for Latent Mycobacterium tuberculosis Infection.
    Clin Infect Dis. 2017 May 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. FURIN J, Cox H
    To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 May 26. doi: 10.1093.
    PubMed     Text format    


  68. AIBANA O, Franke MF, Huang CC, Galea JT, et al
    Impact of Vitamin A and Carotenoids on the Risk of Tuberculosis Progression.
    Clin Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. KAWKITINARONG K, Suwanpimolkul G, Kateruttanakul P, Manosuthi W, et al
    Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.
    Clin Infect Dis. 2017;64.
    PubMed     Text format     Abstract available


  70. MANSON AL, Abeel T, Galagan JE, Sundaramurthi JC, et al
    Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics.
    Clin Infect Dis. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. HARAUSZ EP, Leigh J, Garcia-Prats AJ, Furin J, et al
    Stability of Second-Line Tuberculosis Medications Mixed with Milk or Yogurt.
    Clin Infect Dis. 2017 May 6. doi: 10.1093.
    PubMed     Text format    


  72. SEIFERT M, Georghiou SB, Garfein RS, Catanzaro D, et al
    Impact of fluoroquinolone use on mortality among a cohort of suspected drug-resistant tuberculosis patients.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. WALKER NF, Wilkinson KA, Meintjes G, Tezera LB, et al
    Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. HEEMSKERK AD, Nguyen MTH, Dang HTM, Vinh Nguyen CV, et al
    Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen.
    Clin Infect Dis. 2017 May 4. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  75. AUNG HL, Nyunt WW, Fong Y, Cook GM, et al
    First two extensively drug-resistant tuberculosis cases from Myanmar treated with bedaquiline.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  76. PHILLIPS PP
    Setting tuberculosis regimen development on a firm foundation.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Text format    


  77. BONNETT LJ, Ken-Dror G, Koh G, Davies GR, et al
    Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early phase clinical trials.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  78. RAOULT D
    Old Antibiotics for Tuberculosis.
    Clin Infect Dis. 2017;64:983.
    PubMed     Text format    


  79. BROGER T, Basu Roy R, Filomena A, Greef CH, et al
    Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents.
    Clin Infect Dis. 2017;64:947-955.
    PubMed     Text format     Abstract available


    March 2017
  80. JANSSEN S, Schutz C, Ward A, Nemes E, et al
    Mortality in Severe HIV-TB Associates with Innate Immune Activation and Dysfunction of Monocytes.
    Clin Infect Dis. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. MARKS SM, Mase SR, Bamrah Morris S
    Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. COLLIER D, Iwuji C, Derache A, de Oliveira T, et al
    Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
    Clin Infect Dis. 2017 Mar 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  83. ROCKWOOD N N, Pasipanodya JG, Denti P, Sirgel F, et al
    Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  84. RAVIMOHAN S, Tamuhla N, Nfanyana K, Ni H, et al
    Elevated pre-ART CD39+CD8+ T-cell frequency is associated with early mortality in advanced HIV/TB.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  85. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2017;64:482-489.
    PubMed     Text format    


  86. MARAIS BJ, Heemskerk AD, Marais SS, van Crevel R, et al
    Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.
    Clin Infect Dis. 2017;64:501-509.
    PubMed     Text format    


  87. JOHNSTON JC, Campbell JR, Menzies D
    Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and meta-analysis.
    Clin Infect Dis. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  88. JACOBSON KR, Barnard M, Kleinman MB, Streicher EM, et al
    Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


    January 2017
  89. PROANO A, Bravard MA, Lopez JW, Lee GO, et al
    Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.
    Clin Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2017;64:111-115.
    PubMed     Text format     Abstract available


    December 2016
  91. LEE MR, Huang YP, Kuo YT, Luo CH, et al
    Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  92. CHENG MP, Abou Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  93. CHENG MP, Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis.
    Clin Infect Dis. 2016 Dec 13. doi: 10.1093.
    PubMed     Text format    


  94. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  95. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  96. VINNARD C, King L, Munsiff S, Crossa A, et al
    The Long-Term Mortality of Tuberculosis Meningitis Patients in New York City: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2016
  97. GUMBO T, Makhene MK, Seddon JA
    Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  98. SRIVASTAVA S, Deshpande D, Pasipanodya J, Nuermberger E, et al
    Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  99. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  100. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  101. DESHPANDE D, Srivastava S, Pasipanodya JG, Bush SJ, et al
    Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  102. SRIVASTAVA S, Deshpande D, Pasipanodya JG, Thomas T, et al
    A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  103. SWAMINATHAN S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, et al
    Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


  104. SEDDON JA, Makhene MK
    Harnessing Novel Quantitative Pharmacology Approaches to Optimize the Treatment of Children With Tuberculosis.
    Clin Infect Dis. 2016;63.
    PubMed     Text format    


    October 2016
  105. ALFFENAAR JC, Tiberi S, Verbeeck RK, Heysell SK, et al
    Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  106. NAHID P, Dorman SE, Alipanah N, Barry PM, et al
    Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
    Clin Infect Dis. 2016;63:853-67.
    PubMed     Text format     Abstract available


    September 2016
  107. YANG JY, Han M, Koh Y, Kim WS, et al
    Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  108. BAHR NC, Marais S, Caws M, van Crevel R, et al
    GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  109. HSU DC, Faldetta KF, Pei L, Sheikh V, et al
    A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.
    Clin Infect Dis. 2016;62:258-61.
    PubMed     Text format     Abstract available


    December 2015
  110. GUPTA A, Mathad JS, Abdel-Rahman SM, Albano JD, et al
    Towards Earlier Inclusion of Pregnant and Postpartum Women in TB Drug Trials: Consensus Statements from an International Expert Panel.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    November 2015
  111. RAVIMOHAN S, Tamuhla N, Nfanyana K, Steenhoff AP, et al
    Robust reconstitution of TB-specific polyfunctional CD4+ T-cell responses and rising systemic IL-6 in paradoxical TB-IRIS.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  112. AKKERMAN OW, Odish OF, Bolhuis MS, de Lange WC, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis.
    Clin Infect Dis. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: